AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
Live video webcast on Monday, June 17th at 1:00 PM ET
6月17日周一下午1点(东部时间)直播视频
OCALA, Fla., June 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024 at 1:00 PM ET.
佛罗里达州奥卡拉, 2024年6月10日 — AIM Immunotech股份有限公司。（纽约证券交易所美国：AIM）（“AIM”或“公司”）今天宣布Thomas K. Equels，MS JD，首席执行官AIM将于2024年6月5日星期三参加虚拟投资者午餐会客户系列活动虚拟投资者路演会议将于2024年6月17日星期一美国东部时间下午1:00举行。
As part of the event, Mr. Equels will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.
作为活动的一部分，Equels先生将提供"电梯演讲"，并概述公司即将到来的重要事件。此外，投资者和有兴趣的人在活动期间将有机会实时提交问题。参与公司将在允许的时间内尽可能回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
机器人演示的网络直播视频将在公司网站（aimimmuno.com）的“活动”页面上提供。演示的网络直播视频将在现场演示后两小时提供，并可访问90天。有关AIM Immunotech股份有限公司的信息，请访问aimimmuno.com并与公司联系。(aimimmuno.com)。演讲的网络直播视频将在现场演示后两小时提供，并可访问90天。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫药品公司，专注于研究和开发治疗多种癌症、免疫性疾病和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（吡咯烷寡核苷酸）的首创调节免疫器官的药物，具有广泛的临床试验、覆盖全球重要癌症、病毒性疾病和免疫系统疾病的广谱活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM免疫技术公司是一家专注于研究和开发治疗多种癌症、免疫系统疾病和病毒性疾病（包括COVID-19）药物的免疫药物公司。该公司的主要产品是一种名为Ampligen的一类调节免疫反应的创新药物。Ampligen（Rintatolimod）是一种dsRNA和高选择性TLR3激动剂免疫调节剂，具有广谱的临床试验活性，可用于全球重要癌症、病毒性疾病和免疫系统紊乱的治疗。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
有关更多信息，请访问 aimimmuno.com并联系该公司。X, LinkedIn和Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
投资者联系人：JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com。
